Antitumour prodrug development using cytochrome P450 (CYP) mediated activation

Anti-Cancer Drug Design

Volumn 14, Issue 6, 1999, Pages 473-486

  Patterson, Laurence H ^a   McKeown, Stephanie R ^b   Robson, Tracy ^b   Gallagher, Rebecca ^b   Raleigh, Stuart M ^c   Orr, Samantha ^c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Bioreduction; CYP polymorphism; Cytochrome P450; Gene therapy; Hypoxia; Prodrugs

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTINEOPLASTIC AGENT; AQ 4; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 3A; ETHOXYRESORUFIN DEETHYLASE; IFOSFAMIDE; MESSENGER RNA; NEMORUBICIN; OXAZAPHOSPHORINE DERIVATIVE; OXIDOREDUCTASE; OXYGEN; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

AIR; ANOXIA; BREAST CANCER; CARCINOMA CELL; COLON CANCER; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME METABOLISM; FIBROSARCOMA; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HYPOXIA; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; LYMPHOBLASTOID CELL; MICHAELIS CONSTANT; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA TRANSLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; GENE THERAPY; HUMANS; NEOPLASMS; PRODRUGS;

MURINAE; STAPHYLOCOCCUS PHAGE 3A;

EID: 0033495991     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Alvino E., Gilberti S., Cantagallo D., Massoud R., Gatteschi A., Tentori L., Bonmassar E., Datri S. (1997). In vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds. Cancer Chemotherapy and Pharmacology, 40, 180.
2. Bereziat J.C., Raffalli F., Schmezer P., Frei E., Geneste O., Lang M.A. (1995) Cytochrome P450 2A of nasal epithelium; regulation and role in carcinogen metabolism Molecular Carcinogens, 14, 130.
3. Bertz R., Granneman G. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210.
4. Bickel M. (1969) The pharmacology and biochemistry of N-oxides. Pharmacology, 21, 325.
5. Bremner J.C.M., Bradley J.K., Adams G.E., Naylor M.A., Sansom J.M., Stratford I.J. (1994) Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (pdt). International Journal of Radiation Oncology, Biology and Physics, 29, 329.
6. Brock N. (1989) Oxazaphosphorine cytostatics: past-present-future. Cancer Research, 49, 1.
7. Chomczynski P., Sacchi N. (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162, 156.
8. Dachs G.U., Dougherty G.J., Stratford I.J., Chaplin D.J. (1997) Targeting gene therapy to cancer: a review. Oncology Research, 9, 313.
9. Degroene E.M., Seinen W., Horbach G.J.M.J. (1995) A NIH/3T3 cell-line stability expressing human cytochrome P450/3A4 used in combination with a lacz' shuttle vector to study mutagenicity. European Journal of Pharmacology, 293, 47.
10. Dewaziers I., Cugnenc P., Berger A., Leroux J., Beaune P. (1991a) Drug-metabolizing enzyme expression in human, peritumoral and tumoral colorectal tissue samples. Carcinogenesis, 12, 905.
11. Dewaziers I., Cugnenc P.H., Berger A., Leroux J.P., Beaune P.H. (1991b) Drug-metabolizing enzyme expression in human normal, peritumoral and tumoral colorectal tissue samples. Carcinogenesis 12, 905.
12. Doehmer J., Holtkamp D., Soballa V., Raab G., Schmalix W., Seidel A., Greim H., Jacob J. (1995) Cytochrome-P450 mediated reactions studied in genetically-engineered V79 Chinese-hamster cells. Pharmacogenetics, 5, S91.
13. Douglas J.T., Curiel D.T. (1997) Targeted adenoviral vectors for cancer gene therapy (review). International Journal of Oncology, 11, 341.
14. Feldmann H.J., Molls M., Vaupel P. (1999) Blood flow and oxygenation status of human tumors - clinical investigations. Strahlentherapie und Onkologie, 175, 1.
15. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winick N.J., Cheung N.K.V., Lovett B.D., Nowell P.C., Blair I.A., Rebbeck T.R. (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proceedings of the National Academy of Sciences, USA, 95, 13176.
16. Gerhold D., Rushmore T., Caskey C. (1999) DNA chips: promising toys have become powerful tools. Trends in Biological Science, 24, 168.
17. Gleadle J., Ratcliffe P. (1998) Hypoxia and the regulation of gene expression. Molecular Medicine Today, 122.
18. Hedlund E., Gustafsson J.-A., Warner M. (1998) Cytochrome P450 in the brain: 2B or not 2B. Trends in Pharmacology, 19, 82.
19. Hejmadi M.V., McKeown S.R., Friery O.P., McIntyre I.A., Patterson L.H., Hirst D.G. (1996) DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. British Journal of Cancer, 73, 499.
20. Hong J.Y., Yang C.S. (1997) Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environmental Health Perspectives, 105, 759.
21. Huang Z.Q., Fasco M.J., Figge H.L., Keyomarsi K., Kaminsky L.S. (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metabolism and Disposition, 24, 899.
22. Huang Z.Q., Fasco M.J., Kaminsky L.S. (1997) Alternative splicing of CYP2D mRNA in human breast tissue. Archives of Biochemistry and Biophysics, 343, 101.
23. Hung H.C., Chuang J., Chien Y.C., Chern H.D., Chiang C.P., Kuo Y.S., Hildesheim A., Chen C.J. (1997) Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1: environmental factors and risk of oral cancer. Cancer Epidemiology Biomarkers and Prevention, 6, 901.
24. Ikawa S., Uematsu F., Watanabe K., Kimpara T., Osada M., Hossain A., Sagami I., Kikuchi H., Watanabe M. (1995) Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Pharmacogenetics, 5, S154.
25. Ingelman-Sundberg M. (1999) Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metabolism Reviews, 31, 449.
26. Ingleman-Sundberg M., Oscarson M., McLellan R. (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends in Pharmacological Science, 20, 342.
27. Iscan M., Coban T., Bulbul D., Eke B. C., Aygormez S., Berberoglu U. (1998) Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. European Journal of Drug Metabolism and Pharmacokinetics, 23, 497.
28. Iyer L., Ratain M.J. (1998) Pharmacogenetics and cancer chemotherapy. European Journal of Cancer, 34, 1493.
29. Jounaidi Y., Hecht J.E.D., Waxman D.J. (1998) Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Research, 58, 4391.
30. Kato R., Iwasaki K., Noguchi H. (1978) Reduction of tertiary amine N-oxides by cytochrome P450. Mechanism of the stimulatory effect of flavins and methyl viologen. Molecular Pharmacology, 14, 654.
31. Kim I.H., Brown J.M. (1994) Reoxygenation and rehypoxiation in the SCCVII mouse-tumor. International Journal of Radiation Oncology, Biology and Physics, 29, 493.
32. Kivisto K.T., Fritz P., Linder A., Friedel G., Beaune P., Kroemer H.K. (1995a) Immunohistochemical localization of cytochrome-P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry and Cell Biology, 103, 25.
33. Kivisto K.T., Linder A., Friedel G., Beaune P., Belloc C., Kroemer H.K., Fritz P. (1995b) Immunohistochemical localization of cytochrome-P450 2E1 in human pulmonary-carcinoma and normal bronchial tissue. Virchows Archiv - An International Journal of Pathology, 426, 243-247.
34. Kivisto K.T., Griese E.U., Fritz P., Linder A., Hakkola J., Raunio H., Beaune P., Kroemer H.K. (1996) Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn-Schmiedebergs Archives of Pharmacology, 353, 207.
35. Korzekwa K., Krishnamachary N., Shou M., Ogai A., Parise R., Rettie A., Gonzalez F., Tracy T. (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 24, 4137.
36. Kruger W., Mayer W.K., Schaefer C., Stohrer M., Vaupel P. (1991) Acute changes of systemic parameters in tumor-bearing rats, and of tumor glucose, lactate, and ATP levels upon local hyperthermia and or hyperglycemia. Journal of Cancer Research and Clinical Oncology, 117, 409.
37. Lau D.H.M., Duran G.E., Lewis A.D., Sikic B.I. (1994) Metabolic conversion of methoxymorpholinyl doxorubicin - from a DNA strand breaker to a DNA cross-linker. British Journal of Cancer, 70, 79.
38. Lewis A.D., Lau D.H.M., Duran G.E., Wolf C.R., Sikic B.I. (1992) Role of cytochrome-P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver-microsomes. Cancer Research, 52, 4379.
39. Lewis D.F.V. (1997) Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Drug Metabolism Reviews, 29, 589.
40. Lewis D.F.V., Ioannides C., Parke D.V. (1998) An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. Drug Metabolism Reviews, 30, 709.
41. Lindeke B., Paulsen-Sorman U. (1988) Nitrogenous compounds as ligands to haemoporphyrins, III. The concept of metabolic intermediary complexes. In Progress in Basic Clinical Pharmacology. 1: Biotransformation of Organic Nitrogen Compounds. Cho A.K., Lindeke B. (eds), p. 632. Karger: Basel.
42. Lloyd R.V., Duling D.R., Rumyantseva G.V., Mason R.P., Bridson P.K. (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free-radical. Molecular Pharmacology, 40, 440.
43. Lohr M., Muller P., Karle P., Stange J., Mitzner S., Jesnowski R., Nizze H., Nebe B., Liebe S., Salmons B., Gunzburg W.H. (1998) Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Therapy, 5, 1070.
44. Massaad L., Dewaziers I., Ribrag V., Janot F., Beaune P.H., Morizet J., Gouyette A., Chabot G.G. (1992) Comparison of mouse and human colon tumors with regard to Phase-I and Phase-II drug-metabolizing enzyme-systems. Cancer Research, 52, 6567.
45. Massaad L., Dewaziers I., Ribrag V., Janot F., Morizet J., Beaune P., Gouyette A., Chabot G. (1993) Screening of main drug-metabolizing-enzymes in mouse and human colon tumors. Bulletin Du Cancer, 80, 397.
46. McGhee R.E., Jr, Ronis M.J., Cowherd R.M., Ingleman-Sundberg M., Badger T.M. (1994) Characterisation of cytochrome P450 2E1 in induction in the rat hepatoma FGC-4 cell model by ethanol. Biochemical Pharmacology, 48, 1823.
47. McKay J.A., Murray G.I., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. (1993) Xenobiotic-metabolizing enzyme expression in colonic neoplasia. Gut, 34, 1234.
48. McKeown S.R., Hejmadi M.V., McIntyre I.A., McAleer J.J.A., Patterson L.H. (1995) AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vvivo. British Journal of Cancer, 72, 76.
49. McKeown S.R., Friery O.P., McIntyre I.A., Hejmadi M.V., Patterson L.H., Hirst D.G. (1996) Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. British Journal of Cancer, 74, S39.
50. McKeown S.R., Friery O., Gallagher R., Murray M., Clarke C., Patterson L. H., Hirst D.G. (1998) Enhancement of cyclophosphamide anti-tumour activity with bioreductive drugs AQ4N and tirapazamine. British Journal of Cancer, 78, 45.
51. Mitchell R.T., McFadyen M.C.E., Cheung Y.L., Melvin W.T., Murray G.I. (1998) Cytochrome P450 in renal cell cancer. Journal of Pathology, 184, A30.
52. Muellerklieser W., Schlenger K.H., Walenta S., Gross M., Karbach U., Hoeckel M., Vaupel P. (1991) Pathophysiological approaches to identifying tumor hypoxia in patients. Radiotherapy and Oncology, 20, 21.
53. Murray G.I., Burke M.D. (1995) Immunohistochemistry of drug-metabolizing-enzymes. Biochemical Pharmacology, 50, 895.
54. Murray G.I., McKay J.A., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. (1993a) Cytochrome-P450 expression is a common molecular event in soft-tissue sarcomas. Journal of Pathology, 171, 49.
55. Murray G.I., Weaver R.J., Paterson P.J., Ewen S.W.B., Melvin W.T., Burke M.D. (1993b) Expression of xenobiotic metabolizing enzymes in breast-cancer. Journal of Pathology, 169, 347.
56. Murray G.I., Melvin W.T., Burke M.D. (1995a) Cytochrome-P450 expression in tumors. Journal of Pathology, 176, 323.
57. Murray G.I., Taylor V.E., McKay J.A., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke D. (1995b) The immunohistochemical localization of drug-metabolizing-enzymes in prostate-cancer. Journal of Pathology, 177, 147.
58. Murray G.I., Taylor V.E., McKay J.A., Weaver R.J., Ewen S.W.B., Melvin W.T., Burke M.D. (1995c) Expression of xenobiotic-metabolizing enzymes in tumors of the urinary-bladder. International Journal of Experimental Pathology, 76, 271.
59. Murray G.I., Taylor M.C., Burke M.D., Melvin W.T. (1998) Enhanced expression of cytochrome P450 in stomach cancer. British Journal of Cancer, 77, 1040.
60. Murray G.I., McFadyen M.C.E., Mitchell R.T., Cheung Y.L., Kerr A.C., Melvin W.T. (1999) Cytochrome P450CYP3A in human renal cell cancer. British Journal of Cancer, 79, 1836.
61. Nebert D.W., Ingelman-Sundberg M., Daly A.K. (1999) Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metabolism Reviews, 31, 467.
62. Patterson A.V., Saunders M.P., Chinje E.C., Patterson L.H., Stratford I.J. (1998) Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Design, 13, 541.
63. Patterson L.H. (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA-binding agents - a new class of bioreductive agent. Cancer and Metastasis Reviews, 12, 119-134.
64. Patterson L.H., Raleigh S.M. (1998) Reductive metabolism: its application to prodrug activation. In Gooderham N.J. (ed.), p. 72. Drug Metabolism: Towards the Next Millennium. IOS Press: Amsterdam.
65. Patterson L.H., Craven M.R., Fisher G.R., Teesdalespittle P. (1994) Aliphatic amine N-oxides of DNA-binding agents as bioreductive drugs. Oncology Research, 6, 533.
66. Philip P.A., Kaklamanis L., Ryley N., Stratford I., Wolf R., Harris A., Carmichael J. (1994) Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic-tumors in man. International Journal of Radiation Oncology Biology Physics, 29, 277.
67. Powis G., Wincenttsen L. (1980) Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P450. Biochemical Pharmacology, 29, 347.
68. Puga A., Nebert D.W., McKinnon R.A., Menon A.G. (1997) Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Critical Reviews in Toxicology, 27, 199.
69. Rainov N.G., Dobberstein K.U., SenaEsteves M., Herrlinger U., Kramm C.M., Philpot R.M., Hilton J., Chiocca E.A., Breakefield X.O. (1998) New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Human Gene Therapy, 9, 1261.
70. Raleigh S., Wanogho E., Burke M., McKeown S., Patterson L.H. (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. International Journal of Radiation Oncology, Biology and Physics, 42, 763.
71. Raunio H., Husgafvelpursiainen K., Anttila S., Hietanen E., Hirvonen A., Pelkonen O. (1995) Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene, 159, 113.
72. Riley R.J., Hemingway S.A., Graham M.A., Workman P. (1993) Initial characterization of the major mouse cytochrome-P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR-4233, Win-59075). Biochemical Pharmacology, 45, 1065.
73. Ripamonti M., Pezzoni G., Pesenti E., Pastori A., Farao M., Bargiotti A., Suarato A., Spreafico F., Grandi M. (1992) In vivo antitumor-activity of Fce-23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumor-cells. British Journal of Cancer, 65, 703.
74. Ripamonti M., Capolongo L., Melegaro G., Gornati C., Bargiotti A., Caruso M., Grandi M., Suarato A. (1996) Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. Investigational New Drugs, 14, 139.
75. Schenkman J., Jansson I. (1999) Interactions between cytochrome P450 and cytochrome b5. Drug Metabolism Reviews, 32, 351.
76. Shan X.Q., Aw T.Y., Smith E.R., Ingelman-Sundberg M., Mannervik B., Iyanagi T., Jones D.P. (1992) Effect of chronic hypoxia on detoxication enzymes in rat-liver. Biochemical Pharmacology, 43, 2421.
77. Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V., Korzekwa K.R. (1994) Activation of CYP3A4 - evidence for the simultaneous binding of the two substrates in a cytochrome-P450 active site. Biochemistry, 33, 6450-6455
78. Siim B.G., Menke D.R., Dorie M.J., Brown J.M. (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Research, 57, 2922.
79. Smith D.A., Ackland M.J., Jones B.C. (1997a) Properties of cytochrome P450 isoenzymes and their substrates. 1. Active site characteristics. Drug Discovery Today, 2, 406.
80. Smith D.A., Ackland M.J., Jones B.C. (1997b) Properties of cytochrome P450 isoenzymes and their substrates. 2. Properties of cytochrome P450 substrates. Drug Discovery Today, 2, 479.
81. Smith P.J., Fox M.E., Patterson L.H. (1993) Uptake and intracellular-distribution of anticancer drugs studied by direct imaging and flow-cytometry. Bone Marrow Transplantation, 12, S156.
82. Smith P.J., Desnoyers R., Blunt N., Giles Y., Patterson L.H., Watson J.V. (1997a) Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry, 27, 43-53.
83. Smith P.J., Blunt N.J., Desnoyers R., Giles Y., Patterson L.H. (1997b) DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemotherapy and Pharmacology, 39, 455.
84. Stratford I.J., Workman P. (1998) Bioreductive drugs into the next millennium. Anti-Cancer Drug Design, 13, 519.
85. Sugiura M., Iwasaki K., Kato R. (1976) Reduction of tertiary amine N-oxides by liver microsomal P-450. Molecular Pharmacology, 12, 322.
86. Sugiura M., Iwasaki K., Kato R. (1977) Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P450. Biochemical Pharmacology 26, 489.
87. Toussaint C., Albin N., Maassad L., Grunenwald D., Parise O., Morizet J., Gouyette A., Chabot G. (1993) Main drug and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. Cancer Research, 53, 4608.
88. Ueng Y.F., Kuwabara T., Chun Y.J., Guengerich F.P. (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370.
89. Vaupel P. (1997) Vascularization, blood flow, oxygenation, tissue pH, and bioenergetic status of human breast cancer. Advances in Experimental Medicine and Biology, 411, 243.
90. Vaupel P., Kallinowski F., Okunieff P. (1989) Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors - a review. Cancer Research, 49, 6449.
91. Walton M.I., Workman, P. (1993) Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (Win-59075-SR-4233-NSC-130181) in mice. Journal of Pharmacology and Experimental Therapeutics, 265, 938.
92. Waxman D., Chen L., Hecht J., Jounaidi Y. (1999) Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metabolism Reviews, 31, 503.
93. West W.L., Knight E.M., Pradhan S., Hinds T.S. (1997) Interpatient variability: genetic predisposition and other genetic factors. Journal of Clinical Pharmacology, 37, 635.
94. Wilson W.R., Denny W.A., Pullen S.M., Thompson K.M., Li A.E., Patterson L.H., Lee H.H. (1996) Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. British Journal of Cancer, 74, S43.
95. Woodrooffe A., Bayliss M., Park G. (1995) The effects of hypoxia on drug-metabolizing enzymes. Drug Metabolism Reviews, 27, 471.
96. Workman P., Stratford I.J. (1993) The experimental development of bioreductive drugs and their role in cancer-therapy. Cancer and Metastasis Reviews, 12, 73.
97. Zanger R.C., Novac R.F. (1998) Posttranslational evaluation of cytochrome P450 3A levels and activity by dimethyl sulfoxide. Archives of Biochemistry and Biophysics, 353, 1.